At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 9,902 enrolled
Drug / intervention
S-268019-b +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Observer-Blind, Placebo- Controlled Cross-over Study to Evaluate the Efficacy, Safety, and Immunogenicity of S-268019 for the Prevention of COVID-19
In Brief
A Phase 3 clinical trial evaluating S-268019-b and Placebo for SARS-CoV-2. Completed, enrolled 9,902 participants across 1 site.
Detailed Summary
The main purpose of this study is to assess the efficacy of S-268019-b for the prevention of COVID-19 in the initial vaccination period prior to crossover in participants without evidence of infection before vaccination as compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2
CountriesVietnam
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
Enrollment StartDec 2021
First PostedJan 2022
Primary CompletionDec 2022
Study CompletionJul 2023
TodayJul 2026
First PostedJan 28, 2022
Enrollment StartDec 25, 2021
Primary CompletionDec 19, 2022
Study CompletionJul 19, 2023
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 4.4 years ago
Interventions
S-268019-bdrug
Solution for IM injection
Placebodrug
Saline solution for IM injection